Vitema Pharmaceuticals hits €100M investment milestone under new leadership with €10M capital boost in 6 months
July 5, 2024
With over 20 years of experience in the pharmaceutical industry, Vitema Pharmaceuticals stands as one of the largest and most modern GMP-certified pharmaceutical manufacturing facilities in Europe. Strategically located in Sibiu, Transylvania, the factory comprises four production units spanning a total area of 33,000 square metres, a storage capacity of up to 2,800 pallets, several state-of-the-art laboratories, a research and development centre with qualified staff and 100% automated manufacturing process. This positions Vitema Pharmaceuticals as a centre of excellence for the development, production, and packaging of medicines and dietary supplements to the highest quality standards.
The company specialises in contract manufacturing services (CMO) for pharmaceuticals and dietary supplements, adhering to pharmaceutical industry quality standards. This commitment is confirmed by EU GMP certifications and authorisation to conduct clinical trials. Pharmaceutical GMP certification is subject to the highest level of scrutiny and regulation due to the stringent requirements needed to ensure the safety, efficacy, and consistency of medicines, unlike GMP standards for dietary supplements, although important, are generally less complex and rigorous as dietary supplements are considered a different category of products with inherently lower risks. Manufacturing dietary supplements to pharmaceutical standards is a strong differentiator for Vitema Pharmaceuticals in terms of contract manufacturing services for nutritional supplement companies.
Vitema also provides private labelling services from idea to shelf positioning and has all the necessary capabilities to handle both small- and large-scale production of a range of products including capsules, film-coated and uncoated tablets, chewable tablets, powders as well as injectables, prefilled syringes and vials. The annual capacity of the facility is 3.5 billion capsules and tablets, 4500 tonnes of powders, and 20 million commercial units.
Major changes for Vitema Pharmaceuticals: a new management team, investments of €10 million over the last 6 months, and new strategic partnerships.
With assets worth over €100 million, production facilities equipped to the highest European standards, large-scale production capacity, and quality certifications such as EU GMP pharma, ISO 9001, ISO 22000, and Food Safety Management certification, Vitema Pharmaceuticals is one of the most modern and largest plants in South Eastern Europe and has all the necessary conditions to become one of the largest contract manufacturing companies globally.
Vitema Pharmaceuticals is in a phase of continuous growth and to achieve the company’s most ambitious goals, several major changes have taken place in the last year such as the strengthening of the management team by joining top industry specialists: Abdul Yassin as CEO, Diana Șerban, Commercial & Business Development Head, and Neil Carlsson, Head of R&D and NPD.
The new CEO, Abdul Yassin, holds a PhD in pharmacy and is also an entrepreneur with a strong background in the pharmaceutical and nutritional supplements industry, as well as an active member of the global business community. He is committed to changing the rules in his industry through his innovative approaches:

“At Vitema Pharmaceuticals, our approach is not only about meeting existing standards but also about redefining new higher standards for safety and efficacy. By manufacturing supplements according to pharmaceutical GMP standards, we ensure that every product that leaves our manufacturing facilities has a high degree of purity, and safety, and accurately reflects its labelling. We believe it’s time for a change in the supplement industry as well, a transition to honesty and complete accountability to consumers. We invite you to join us in this vital mission. Together we can create an environment where consumers can trust the supplements they use, and companies can take pride in the products they offer.” – Abdul Yassin
Diana Șerban brings a wealth of experience in the pharmaceutical industry, having spent over 8 years in key roles focused on product development, marketing, and sales within prominent companies in the Romanian pharmaceutical market. Diana is a graduate of the University of Medicine and Pharmacy, holding an undergraduate degree, and furthered her education by earning a Master’s degree in Business Administration.
Currently serving as the Commercial & Business Development Head, Diana plays a pivotal role in driving Vitema Pharmaceuticals towards becoming a centre of excellence for contract manufacturing services. With an innovation-driven vision, Diana is focused on strengthening the company’s services, expanding strategic partnerships, and championing operational excellence:

“Vitema Pharmaceuticals aims through all its actions to strengthen its position as a key partner for contract manufacturing services, recognised both nationally and internationally. Guided by a passion for excellence, commitment to quality and safety, accountability and commitment, the Vitema team aims to revolutionise contract manufacturing services by offering a full range of products and services, covering therapeutic areas of major importance.” – Diana Șerban

With a Master’s degree in Research Methodology and over 15 years of experience in the Nutraceutical industry, Neil Carlsson has extensive experience in the field, innovating and developing products, collaborating throughout his career with global brands, teams, and athletes motivated by the latest research. From 2023, Neil leads the state-of-the-art R&D Centre at Vitema Pharmaceuticals. The department is distinguished by its skills in formulation, process optimisation, and dosage form innovation. State-of-the-art technologies and platforms are used to drive drug development in line with advances in the pharmaceutical industry.
Partnership with AI Clinical Research for clinical trials and bioequivalence analysis.
Vitema Pharmaceuticals has partnered with AI Clinical Research, whose team operates Vitema’s state-of-the-art bioanalytical laboratory. AI Clinical Research is the new approach for an independent full-service company in the area of clinical research based on the newest technology with national coverage and providing clinical trial-related services to pharmaceutical, medical devices, and biotechnology companies. AI Clinical Research is part of a global local CROs network that allows AI Clinical Research to provide clinical trial services in Europe, the US, Canada, the Middle East, Africa, and Southeast Asia.
Vitema Pharmaceuticals enters into a strategic contract manufacturing partnership with DY Nutrition Global SA, one of the leading players in the dietary supplement industry.
Vitema’s new management has achieved another significant milestone through the establishment of a strategic partnership with DY Nutrition Global SA, one of the major players in the dietary supplement industry, founded by legendary bodybuilder Dorian Yates.
As part of this partnership, DY Nutrition Global SA is in the process of transferring its entire production worth €15 million per year to Vitema’s site, highlighting the trust and confidence in Vitema’s capabilities.
Post Related
Social Media
Main Menu
Vitema
Manufacturing
Copyright © 2024 Vitema Pharmaceuticals

